DDIs with perpetrator compounds that induce CYP2C

VictimPerpetrator% Change AUCVictim Dose (Oral)Perpetrator Dose (Oral)References
Tolbutamide CYP2C9 in vivo probeAprepitant−30.8500 mg125/80 mg (3 days)(Shadle et al., 2004)
Tolbutamide CYP2C9 in vivo probeRifampicin−62.5500 mg600 mg (14 days)(Adams et al., 2005)
Tolbutamide CYP2C9 in vivo probeRitonavir−50.5500 mg200-400 mg (average of 14 days)(Kirby et al., 2011)
(S)-warfarin CYP2C9 in vivo probeBosentan−29.326 mg500 mg (10 days)(Weber et al., 1999)
(S)-warfarin CYP2C9 in vivo probeDalcetrapib−145 mg of racemic warfarin900 mg (7 days)(Derks et al., 2009)
(S)-warfarin CYP2C9 in vivo probeRifampicin−74.40.75 mg/kg300 mg (14 days)(Heimark et al., 1987)
(S)-warfarin CYP2C9 in vivo probeRitonavir−24.310 mg100 mg (14 days)(Morcos et al., 2013)
Repaglinide CYP2C8 in vivo probeRifampicin−79.64 mg600 mg (7 days)(Bidstrup et al., 2004)
Repaglinide CYP2C8 in vivo probeFlucloxacillin−46.84 mg500 mg (7 days)(Du et al., 2013)
Omeprazole CYP2C19 in vivo probeArbamazepine−39.720 mg400-600 mg/day (3 weeks)(Bertilsson et al., 1997)
Omeprazole CYP2C19 in vivo probeEfavirenz−46.420 mg600 mg (17 days)(Michaud et al., 2012)
Omeprazole CYP2C19 in vivo probeEnzalutamide−70.520 mg160 mg (85 days)(Gibbons et al., 2015)
Omeprazole CYP2C19 in vivo probeRifampicin−9310 mg600 mg (7 days)(Derungs et al., 2016)